{"id":4300,"date":"2025-08-09T23:35:30","date_gmt":"2025-08-09T20:35:30","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4300"},"modified":"2025-08-09T23:35:32","modified_gmt":"2025-08-09T20:35:32","slug":"revidia-therapeutics-msi-1436-duchenne-muscular-dystrophy-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/revidia-therapeutics-msi-1436-duchenne-muscular-dystrophy-dmd\/","title":{"rendered":"Revidia Therapeutics MSI-1436, DMD Hastalar\u0131nda Kalp Yetmezli\u011finin Tedavisinde Umut Vaat Ediyor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">\u0130nsan v\u00fccudunun hasarl\u0131 kalp kas\u0131n\u0131 yenileyebilece\u011fi gibi ger\u00e7ek\u00e7i olmayan bir fikre ra\u011fmen, insan bebekleri ciddi bir miyokard enfarkt\u00fcs\u00fcnden sonra miyokard hasar\u0131n\u0131 onarabilir ve normal kalp fonksiyonlar\u0131n\u0131 tamamen geri kazanabilirler. <strong>Revidia Therapeutics&#039;nin ba\u015fl\u0131ca ila\u00e7 aday\u0131, yeti\u015fkin memeli kalbinde rejenerasyonu aktive etti\u011fi g\u00f6sterilen ilk k\u00fc\u00e7\u00fck molek\u00fcl olan MSI-1436&#039;d\u0131r.<\/strong><\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#the-risk-of-heart-failure-in-patients-diagnosed-with-dmd\">DMD tan\u0131s\u0131 alm\u0131\u015f hastalarda kalp yetmezli\u011fi riski<\/a><\/li><li><a href=\"#genetic-therapies-for-dmd\">DMD i\u00e7in ekzon atlama ve gen terapileri<\/a><\/li><li><a href=\"#no-stem-cell-regenerative-medicine-therapy-has-received-fda-approval\">Hi\u00e7bir k\u00f6k h\u00fccre rejeneratif t\u0131p tedavisi FDA onay\u0131 almad\u0131<\/a><\/li><li><a href=\"#mission-of-revidia-therapeutics\">Revidia Therapeutics&#039;nin Misyonu<\/a><\/li><li><a href=\"#what-is-msi-1436\">MSI-1436 nedir?<\/a><\/li><li><a href=\"#competitive-benefits-of-drugs-with-small-molecules\">K\u00fc\u00e7\u00fck Molek\u00fcll\u00fc \u0130la\u00e7lar\u0131n Rekabet\u00e7i Faydalar\u0131<\/a><\/li><li><a href=\"#what-does-revidia-therapeutics-say\">Revidia Therapeutics Ne Diyor?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-risk-of-heart-failure-in-patients-diagnosed-with-dmd\">DMD tan\u0131s\u0131 alm\u0131\u015f hastalarda kalp yetmezli\u011fi riski<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130nsan genomundaki en b\u00fcy\u00fck ve en karma\u015f\u0131k gen olan distrofin genindeki mutasyonlar, X&#039;e ba\u011fl\u0131 bir yetim hastal\u0131k olan Duchenne kas distrofisine (DMD) yol a\u00e7ar. Distrofin ad\u0131 verilen b\u00fcy\u00fck bir yap\u0131sal protein, kas h\u00fccrelerini kas\u0131lman\u0131n yol a\u00e7t\u0131\u011f\u0131 zararlardan korur. Mevcut teknoloji, DMD&#039;ye neden olan distrofin mutasyonlar\u0131n\u0131 tamamen d\u00fczeltemez veya distrofin geninin boyutu ve karma\u015f\u0131kl\u0131\u011f\u0131 nedeniyle insan h\u00fccrelerine tam uzunlukta bir distrofin transgeni yerle\u015ftiremez. DMD \u015fu anda tedavi edilemez durumdad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD, genellikle \u015fiddetli ve ilerleyici kas y\u0131k\u0131m\u0131na yol a\u00e7an bir iskelet kas\u0131 hastal\u0131\u011f\u0131 olarak d\u00fc\u015f\u00fcn\u00fclse de, bir kalp hastal\u0131\u011f\u0131d\u0131r. 20&#039;li ya\u015flar\u0131n ortalar\u0131nda veya sonlar\u0131nda, DMD hastalar\u0131n\u0131n \u00e7o\u011fu kalp yetmezli\u011finden hayat\u0131n\u0131 kaybeder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD hastalar\u0131 genellikle ergenlik \u00e7a\u011f\u0131n\u0131n ba\u015flar\u0131nda y\u00fcr\u00fcme yetene\u011fini kaybeder ve semptomlar genellikle 3 ila 5 ya\u015flar\u0131 aras\u0131nda ba\u015flar. Kalpteki distrofin aktivitesinin kayb\u0131ndan kaynaklanan kalp kas\u0131 dejenerasyonu, sonunda dilate kardiyomiyopati ve kalp yetmezli\u011fine yol a\u00e7ar. Kalbin kan pompalama kapasitesi, dilate kardiyomiyopati nedeniyle zay\u0131flar ve bu da ventrik\u00fcllerin \u015fi\u015fmesine ve duvarlar\u0131n\u0131n incelmesine neden olur. Kardiyomiyopati, DMD hastalar\u0131n\u0131n \u00e7o\u011funda ergenlik \u00e7a\u011f\u0131n\u0131n sonlar\u0131nda g\u00f6r\u00fcl\u00fcr ve \u00e7ocuklarda 10 ya\u015f gibi erken bir ya\u015fta bile tespit edilebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD kardiyomiyopatisi \u00f6l\u00fcme katk\u0131da bulunsa da, \u015fu anda onayl\u0131 bir tedavisi bulunmamaktad\u0131r ve kalp ila\u00e7lar\u0131 geli\u015ftirme \u00e7abalar\u0131 asgari d\u00fczeydedir. G\u00fcn\u00fcm\u00fczde DMD kalp tedavisinde, inflamasyon, stres ve yeniden \u015fekillenmenin kalbe verdi\u011fi hasar\u0131 azaltmak i\u00e7in steroidler ve di\u011fer geleneksel kalp yetmezli\u011fi ila\u00e7lar\u0131 kullan\u0131lmaktad\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"genetic-therapies-for-dmd\">DMD i\u00e7in ekzon atlama ve gen terapileri<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">DMD&#039;yi tedavi etmek i\u00e7in genetik tedavilerin geli\u015ftirilmesine b\u00fcy\u00fck kaynak ve \u00f6zen harcanm\u0131\u015ft\u0131r. Gen transfer tedavisi ve ekzon atlama, ABD&#039;de onaylanm\u0131\u015f genetik tekniklere \u00f6rnektir. Ekzon atlama tedavilerinde, distrofin geninin mutant b\u00f6lgelerini &quot;atlamak&quot; i\u00e7in tasarlanm\u0131\u015f antisens oligon\u00fckleotidler (AON&#039;ler) kullan\u0131l\u0131r. DMD hastalar\u0131n\u0131n k\u00fc\u00e7\u00fck bir k\u0131sm\u0131nda, AON&#039;ler belirli distrofin mutasyon tiplerini hedef al\u0131r. Gen transfer tedavileri, viral vekt\u00f6rler kullan\u0131larak iskelet kas\u0131 h\u00fccrelerine k\u0131smi veya &quot;mikro-distrofin&quot; transgeni enjekte eder. \u2013 Devam\u0131n\u0131 Oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" data-type=\"post\" data-id=\"1445\" rel=\"noreferrer noopener\">Ekzon Atlama Nedir?<\/a> \u2013<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD, ekzon atlama veya mikrodistrofin gen transferi tedavileriyle tedavi edilemez. Her iki strateji de, k\u0131smen i\u015flev g\u00f6ren, k\u0131salt\u0131lm\u0131\u015f distrofin proteinlerinin ekspresyonunu art\u0131rarak iskelet kas\u0131 ile ili\u015fkili semptomlar\u0131 azaltmay\u0131 ama\u00e7lamaktad\u0131r. ABD&#039;de h\u0131zl\u0131 FDA kullan\u0131m\u0131na izin verilmi\u015f olmas\u0131na ra\u011fmen, her iki strateji de g\u00fcvenilir ve tutarl\u0131 bir klinik etkinlik g\u00f6stermemi\u015ftir. Mikrodistrofin gen transferi tedavilerinde de ciddi g\u00fcvenlik sorunlar\u0131 mevcuttur. FDA&#039;deki son liderlik de\u011fi\u015fiklikleri, kurumun bu t\u00fcr genetik ila\u00e7lar i\u00e7in h\u0131zland\u0131r\u0131lm\u0131\u015f onay prosed\u00fcr\u00fc hakk\u0131nda soru i\u015faretlerine yol a\u00e7m\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Genetik ve di\u011fer iskelet kas\u0131 hedefli tedavilerin, DMD hastalar\u0131nda ana \u00f6l\u00fcm nedeni olan dilate kardiyomiyopati ve bunun sonucunda ortaya \u00e7\u0131kan kalp yetmezli\u011fini tedavi etmemesi bir di\u011fer \u00f6nemli dezavantajd\u0131r. Dahas\u0131, kalp fonksiyonunu art\u0131rmadan iskelet kas\u0131 aktivitesini \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131ran herhangi bir tedavi, kardiyak morbidite ve mortaliteyi art\u0131rabilir. \u0130skelet kas\u0131 performans\u0131n\u0131n iyile\u015ftirilmesi i\u00e7in daha fazla kan ak\u0131\u015f\u0131 gereklidir ve bu da zaten risk alt\u0131nda olan bir kalbin i\u015f y\u00fck\u00fcn\u00fc art\u0131r\u0131r. Bu nedenle, DMD&#039;nin en ba\u015far\u0131l\u0131 tedavisi i\u00e7in hem iskelet hem de kalp kas\u0131 i\u015flev bozuklu\u011funu ele alan tek bir tedavi ajan\u0131 veya tedavi kombinasyonlar\u0131 gerekli olacakt\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"no-stem-cell-regenerative-medicine-therapy-has-received-fda-approval\">Hi\u00e7bir k\u00f6k h\u00fccre rejeneratif t\u0131p tedavisi FDA onay\u0131 almad\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Rejeneratif t\u0131p, uzun zamand\u0131r kardiyolojinin kalp hasar\u0131n\u0131 tedavi etme umutlar\u0131n\u0131n temel ta\u015f\u0131 olmu\u015ftur. Kalp onar\u0131m\u0131 ve rejenerasyonunu sa\u011flamak i\u00e7in, rejeneratif t\u0131p i\u015fletmelerinin \u00e7o\u011fu k\u00f6k\/progenit\u00f6r h\u00fccre nakli ve inf\u00fczyon teknikleri geli\u015ftirmeye odaklanm\u0131\u015ft\u0131r. Nakledilen veya inf\u00fcze edilen k\u00f6k h\u00fccrelerin kalp dokusuna yerle\u015fmedi\u011fi art\u0131k yayg\u0131n olarak bilinmektedir. &quot;Parakrin hipotezi&quot;, bu h\u00fccrelerin i\u00e7sel onar\u0131m ve rejeneratif s\u00fcre\u00e7leri destekleyen maddeler salg\u0131lama kapasitesinin, seyrek, k\u00fc\u00e7\u00fck ve son derece tutars\u0131z terap\u00f6tik etkilere neden oldu\u011funu varsayar. Bu fakt\u00f6rlerin ne oldu\u011fu ve hangi sinyal yollar\u0131n\u0131 aktive ettikleri belirsizdir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">20 y\u0131l\u0131 a\u015fk\u0131n s\u00fcren titiz ara\u015ft\u0131rma ve geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131na ra\u011fmen, FDA taraf\u0131ndan hi\u00e7bir k\u00f6k h\u00fccre rejeneratif t\u0131p tedavisi onaylanmam\u0131\u015ft\u0131r. K\u00f6k h\u00fccre tedavileri, y\u00fcksek maliyetleri, \u00f6nemli \u00fcretim sorunlar\u0131, s\u0131n\u0131rl\u0131 etkinlikleri ve karma\u015f\u0131kl\u0131klar\u0131 nedeniyle zorluklarla kar\u015f\u0131la\u015fmaya devam etmektedir. Bunlardan biri, DMD&#039;li ki\u015filerde kalp ve iskelet hasar\u0131n\u0131 tedavi etmek i\u00e7in geli\u015ftirilmekte olan deramiocel&#039;dir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">K\u00fclt\u00fcrlenmi\u015f kardiyak progenit\u00f6r h\u00fccreler kullanan Deramiocel, \u00fc\u00e7 ayda bir inf\u00fcze edilen deneysel bir allojenik h\u00fccre tedavisidir. Enjekte edilen h\u00fccreler, imm\u00fcnomod\u00fclat\u00f6r ve di\u011fer doku onar\u0131m yeteneklerine sahip parakrin maddeler i\u00e7eren k\u00fc\u00e7\u00fck vezik\u00fcller salg\u0131lar. Deramiocel&#039;nin pazarlama ba\u015fvurusu, deneysel tedavinin &quot;etkilili\u011fe dair \u00f6nemli kan\u0131t i\u00e7in yasal gereklili\u011fi kar\u015f\u0131lamad\u0131\u011f\u0131n\u0131&quot; belirten FDA taraf\u0131ndan yak\u0131n zamanda reddedildi. FDA ayr\u0131ca CMC (kimya, \u00fcretim ve kontroller) ile ilgili endi\u015felerini dile getirdi. Devam\u0131n\u0131 Oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-deramiocel\/\" target=\"_blank\" data-type=\"post\" data-id=\"2226\" rel=\"noreferrer noopener\">Deramiocel Nedir?<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"mission-of-revidia-therapeutics\">Revidia Therapeutics&#039;nin Misyonu<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Revidia Therapeutics&#039;nin amac\u0131, do\u011fal kalp yenilenmesini ve onar\u0131m\u0131n\u0131 uyaran t\u00fcr\u00fcn\u00fcn ilk \u00f6rne\u011fi olan k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar yaratmakt\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kardiyak rejeneratif t\u0131p konusunda Revidia Therapeutics farkl\u0131 bir strateji benimsemi\u015ftir. \u015eirket, insan kalbi ve di\u011fer organlar\u0131n\u0131n do\u011fumdan hemen sonra devre d\u0131\u015f\u0131 kalan g\u00fc\u00e7l\u00fc do\u011fal iyile\u015fme ve onar\u0131m mekanizmalar\u0131na sahip oldu\u011fu ilkesi \u00fczerine kurulmu\u015ftur. \u015eiddetli bir miyokard enfarkt\u00fcs\u00fcnden sonra, insan yenido\u011fanlar\u0131 miyokard hasar\u0131n\u0131 onarabilir ve normal kalp fonksiyonlar\u0131n\u0131 tamamen geri kazanabilirler, ancak insan v\u00fccudunun hasarl\u0131 kalp kas\u0131n\u0131 yenileyebilece\u011fi fikri ger\u00e7ek\u00e7i g\u00f6r\u00fcnmeyebilir. Yenido\u011fan b\u00fcy\u00fcd\u00fck\u00e7e bu yetenek kaybolur. Bir\u00e7ok hayvan ya\u015famlar\u0131 boyunca karma\u015f\u0131k doku ve organlar\u0131 yenileme kapasitesini korur ve di\u011fer yenido\u011fan memeliler de ayn\u0131 kapasiteye sahiptir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-msi-1436\">MSI-1436 nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Yeti\u015fkin memeli kalbinde rejenerasyonu uyard\u0131\u011f\u0131 g\u00f6sterilen ilk k\u00fc\u00e7\u00fck molek\u00fcl olan MSI-1436, \u015firketin en iyi tedavi aday\u0131d\u0131r. Revidia Therapeutics, alt\u0131 farkl\u0131 kalp hasar\u0131 t\u00fcr\u00fc de dahil olmak \u00fczere \u00fc\u00e7 hayvan t\u00fcr\u00fcnde ve \u00e7ok say\u0131da hasar modelinde, MSI-1436&#039;n\u0131n kalp kas\u0131 ve di\u011fer dokular\u0131n onar\u0131m\u0131n\u0131 ve rejenerasyonunu ne kadar iyi uyard\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"competitive-benefits-of-drugs-with-small-molecules\">K\u00fc\u00e7\u00fck Molek\u00fcll\u00fc \u0130la\u00e7lar\u0131n Rekabet\u00e7i Faydalar\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130la\u00e7 sekt\u00f6r\u00fc ve t\u0131p, b\u00fcy\u00fck \u00f6l\u00e7\u00fcde k\u00fc\u00e7\u00fck molek\u00fcllere dayanmaktad\u0131r. K\u00fc\u00e7\u00fck molek\u00fcller, \u015fu anda geli\u015ftirilmekte olan di\u011fer kardiyak rejeneratif t\u0131p tedavilerine k\u0131yasla \u015fu rekabet avantajlar\u0131n\u0131 sa\u011flar: 1) g\u00f6receli maliyet etkinli\u011fi, 2) uygulama kolayl\u0131\u011f\u0131 ve 3) olumsuz bir reaksiyon durumunda kolayca geri d\u00f6nd\u00fcr\u00fclebilirlik.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>MSI-1436&#039;n\u0131n \u00f6nemli bir avantaj\u0131, insanlardaki g\u00fcvenlik profilinin halihaz\u0131rda iyi belirlenmi\u015f olmas\u0131d\u0131r. MSI-1436&#039;n\u0131n tip 2 diyabet ve obezite i\u00e7in olas\u0131 bir tedavi olarak kullan\u0131m\u0131na ili\u015fkin Faz 1\/1b klinik \u00e7al\u0131\u015fmalar\u0131, 2008 y\u0131l\u0131nda Genaera Corporation taraf\u0131ndan y\u00fcr\u00fct\u00fclm\u00fc\u015ft\u00fcr.<\/strong> Bu klinik \u00e7al\u0131\u015fmalara g\u00f6re, MSI-1436&#039;n\u0131n kalp rahats\u0131zl\u0131klar\u0131n\u0131n tedavisinde y\u00fcksek bir terap\u00f6tik indekse sahip oldu\u011fu tahmin edilmektedir. Genaera taraf\u0131ndan belirlenen en y\u00fcksek iyi tolere edilen doz, hayvan modellerinde doku yenilenmesini destekleyen ve kalp fonksiyonunu iyile\u015ftiren MSI-1436 dozlar\u0131ndan be\u015f ila elli kat daha y\u00fcksektir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-does-revidia-therapeutics-say\">Revidia Therapeutics Ne Diyor?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">DMD&#039;nin y\u0131prat\u0131c\u0131 do\u011fas\u0131, DMD hastalar\u0131nda birincil \u00f6l\u00fcm nedenine y\u00f6nelik kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7, kapsaml\u0131 etkinlik testleri, k\u00fc\u00e7\u00fck molek\u00fcll\u00fc ila\u00e7lar\u0131n k\u00f6k h\u00fccre bazl\u0131 tedavilere k\u0131yasla bir\u00e7ok faydas\u0131, genetik DMD tedavilerinin s\u00fcregelen zorluklar\u0131 ve en \u00f6nemlisi MSI-1436&#039;n\u0131n kan\u0131tlanm\u0131\u015f insan g\u00fcvenli\u011fi de dahil olmak \u00fczere \u00e7ok say\u0131da fakt\u00f6r, devam eden ara\u015ft\u0131rma ve geli\u015ftirme programlar\u0131n\u0131 ve klinik geli\u015ftirme planlar\u0131n\u0131 etkilemi\u015ftir. Distrofin genindeki anormalliklerden kaynaklanan kal\u0131tsal kas bozukluklar\u0131 olan distrofinopatilerin tedavisi i\u00e7in Revidia Therapeutics, FDA Yetim \u0130la\u00e7 olarak belirlenmi\u015ftir. ODD, DMD hastalar\u0131nda kullan\u0131m\u0131 onaylan\u0131rsa MSI-1436&#039;ya yedi y\u0131ll\u0131k pazar m\u00fcnhas\u0131rl\u0131\u011f\u0131 sa\u011flayacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MSI-1436 \u015fu anda klinik \u00f6ncesi geli\u015ftirmenin son a\u015famalar\u0131nda olup, 2026 y\u0131l\u0131nda bir IND ba\u015fvurusunun yap\u0131lmas\u0131 bekleniyor. <strong>MSI-1436&#039;n\u0131n, hastal\u0131\u011f\u0131n tedavisinde etkili oldu\u011fu kan\u0131tlan\u0131rsa ve hastalar taraf\u0131ndan kullan\u0131m\u0131na izin verilirse, hastalar\u0131n ya\u015fam kalitesini iyile\u015ftirmesi, ya\u015fam s\u00fcrelerini uzatmas\u0131 ve DMD kardiyomiyopatisinin hastalar ve bak\u0131c\u0131lar\u0131 \u00fczerindeki psikososyal etkilerini azaltmas\u0131 bekleniyor.<\/strong> DMD kardiyomiyopatisinin \u00f6tesinde, MSI-1436&#039;n\u0131n kalp d\u0131\u015f\u0131ndaki dokularda da \u00e7ok say\u0131da potansiyel rejeneratif t\u0131p kullan\u0131m\u0131na sahip olmas\u0131n\u0131 umuyoruz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/www.nature.com\/articles\/s41536-017-0008-1\" target=\"_blank\" rel=\"noreferrer noopener\">Protein tirozin fosfataz 1B inhibit\u00f6r\u00fc MSI-1436, kalp ve di\u011fer bir\u00e7ok dokunun yenilenmesini uyar\u0131r<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Human babies may indeed repair myocardial damage and fully recover normal cardiac function following a severe myocardial infarction, despite the seemingly unrealistic idea that the human body can regenerate damaged heart muscle. Revidia Therapeutics\u2019s lead drug candidate is MSI-1436, the first small molecule shown to activate regeneration in the adult mammalian heart. The risk of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4320,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[89,362,404,403,402],"class_list":["post-4300","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-cardiomyopathy","tag-dmd-cardiomyopathy","tag-heart-failure","tag-msi-1436","tag-revidia-therapeutics"],"subtitle":"Revidia Therapeutics'nin, alt\u0131 farkl\u0131 kalp yaralanmas\u0131 t\u00fcr\u00fc de dahil olmak \u00fczere \u00fc\u00e7 hayvan t\u00fcr\u00fcnde ve \u00e7ok say\u0131da hasar modelinde, MSI-1436'n\u0131n kalp kas\u0131 ve di\u011fer dokular\u0131n onar\u0131m\u0131n\u0131 ve yenilenmesini ne kadar iyi uyard\u0131\u011f\u0131n\u0131 g\u00f6sterdi.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4300"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4300\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4320"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}